- Novavax (NASDAQ:NVAX) announced on Friday that the company started the administration of the first booster doses in the pediatric expansion of a late-stage trial being conducted in the U.S. and Mexico for its COVID-19 vaccineNVX-CoV2373.
- The PREVENT-19 trial, involving nearly 30,000 subjects, is one of the two pivotal trials the company is advancing to study NVX-CoV2373.
- Accordingly, the children aged 12 through 17 years will receive a third dose of the protein-based shot at least five months after the administration of the active vaccine.
- The booster dose will be similar to the active vaccine comprising a two-dose regimen of 5 micrograms of recombinant spike protein combined with 50 micrograms of Matrix-M adjuvant.
- The study designed to evaluate the safety and immunogenicity of the third dose in the age group is expected to generate initial results in 2H 2022, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments